Clinical trials: Malignant Solid Neoplasm, open to volunteers
Advanced Solid Tumor
A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and preliminary anti-tumor activity of HS-10386 in participants with advanced solid tumors who have failed prior treatments.
- Trial name
- NCT05911464
- Testing
- HS-10386
- Where
- China
- Volunteers
- 248 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Solid Tumor
Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors
This is a phase I/II study to investigate the safety, tolerability, and preliminary efficacy of GLS-012 monotherapy and in combination with GLS-010 in subjects with advanced solid rumor after progression on standard treatment.
- Trial name
- NCT05909436
- Testing
- GLS-012, GLS-010
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
Locally Advanced or Metastatic Solid Tumors
IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors
The goal of this first-in-human, single-center, prospective, open-label, phase 1/2 trial is to evaluate the safety and efficacy of the interferon alpha expressing mesenchymal stromal cells (MSC-IFNα) combined with or without…
- Trial name
- NCT05699811
- Testing
- MSC-IFNα, Nab paclitaxel, Cyclophosphamide
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chinese PLA General Hospital
Advanced Solid Tumors
A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients
The purpose of the study is to evaluate safety, pharmacokinetics,immunogenicity and efficacy of QLS31903 alone in the treatment of advanced cancer.
- Trial name
- NCT05823285
- Testing
- QLS31903
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
TCR-T Cells, Refractory Solid Tumors
KSX01-TCRT Injection Project in Solid Tumors
1) Safety and efficacy of TCR-T cells in subjects with refractory/relapsed solid tumors. 2) The activation and proliferation of TCR-T cells in the subject, and the survival time.
- Conditions
- TCR-T Cells, Refractory Solid Tumors, Relapsed Solid Tumors
- Trial name
- NCT05811975
- Testing
- KSX01-TCRT injection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- TCRx Therapeutics Co.Ltd
Cancer, Cancer of Pancreas
Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors
This is a Phase 1b study to assess the safety and tolerability of STI-1386, an oncolytic virus, in subjects with relapsed and refractory solid tumors (RRSTs).
- Conditions
- Cancer, Cancer of Pancreas, Sarcoma, Hepatic Metastasis
- Trial name
- NCT05361954
- Testing
- STI-1386
- Volunteers
- 36 people
- Sponsor
- Sorrento Therapeutics, Inc.
Advanced Solid Tumors
A Study of KM501 in Patients With Solid Tumors
A single-arm, open, multicenter Phase I study to evaluate the safety, tolerability, pharmacokinetic profile, and efficacy of the KM501 double-antibody ADC in subjects with advanced solid tumors that express, amplify, or mutate…
- Trial name
- NCT05804864
- Testing
- KM501
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Advanced Solid Tumor
Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors
This study consists of Part A for monotherapy and Part B for combination therapy to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy of TU2218 in patients with advanced solid tumors.
- Trial name
- NCT05204862
- Testing
- TU2218, Anti-PD-1 antibody
- Where
- 3 sites in United States, South Korea
- Volunteers
- 240 people
- Sponsor
- TiumBio Co., Ltd.
Mesothelin-positive Advanced Malignant Solid Tumors
MSLN-targeted CAR-T Cells in Solid Tumors.
This study aims to explore the safety, tolerability and preliminary efficacy of Anti-Mesothelin CAR-T cells in subjects with Mesothelin-positive advanced malignant solid tumors.
- Trial name
- NCT05783089
- Testing
- Anti-mesothelin CAR-T cells
- Volunteers
- 87 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Advanced Solid Tumor
A Study of KM602 in Patients With Advanced Solid Tumors
This study is a Phase 1 open-label, first-in-human, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and activity of KM602 as monotherapy in patients with advanced solid tumors.
- Trial name
- NCT05766527
- Testing
- KM602
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
This phase II trial tests how well CPI-613 (devimistat) in combination with hydroxychloroquine (HCQ) and 5-fluorouracil (5-FU) or gemcitabine works in patients with solid tumors that may have spread from where they first started…
- Conditions
- Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Lung Adenocarcinoma
- Trial name
- NCT05733000
- Testing
- Biospecimen Collection, Computed Tomography, Devimistat
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Northwestern University
Solid Tumor Neoplasms
Exceptional Responders With Solid Tumor Cancer to Chemotherapy
This is an observational study enrolling patients with Solid Tumor cancers to identify genomic expression differences between exceptional responders and non-responders to standard of care chemotherapy.
- Trial name
- NCT02555735
- Testing
- Standard of Care Chemotherapy
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Adera Labs, LLC
Neoplasms, Neoplasm Malignant
AIMS Cancer Outcomes Study
The overall aim is to describe disease-free survival (DFS) in early stage cancer patients and three-year overall survival (OS) outcomes in advanced stage cancer patients receiving Advanced Integrative Oncology (AIO) treatment in…
- Conditions
- Neoplasms, Neoplasm Malignant, Advanced Cancer, Advanced Solid Tumor
- Trial name
- ACOS (NCT04495790)
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Advanced Integrative Medical Science Institute
Advanced Solid Tumor
Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Solid Tumor
Prospective, single-center, single-arm, open-label,interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocyte (TIL) infusion (HS-IT101) after lymphodepletion preparative with…
- Trial name
- NCT05539768
- Testing
- HS-IT101
- Volunteers
- 8 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Solid Tumor, Non Hodgkin Lymphoma
A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors
A Phase 1, open label, multi center, dose escalation and expansion study will assess the safety, tolerability, PK, and preliminary efficacy of SCR-6920 capsule in participants with advanced malignant tumors.
- Trial name
- NCT05528055
- Testing
- SCR-6920 capsule
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Locally Advanced or Metastatic Solid Tumors, Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
A phase I/II study to examine the safety, tolerability, pharmacokinetics and efficacy of XZP-5955 tablets in patients with advanced solid tumors harboring NTRK or ROS1 gene fusion
- Trial name
- NCT04996121
- Testing
- XZP-5955 tablets
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Advanced Cancer, Advanced Solid Tumor
A Study in Patients With Advanced Cancers
A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
- Trial name
- NCT05320588
- Testing
- BIO-106, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 332 people
- Sponsor
- BiOneCure Therapeutics Inc.
Advanced Solid Tumor
A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.
This is a first-in-human, 2-part study to investigate the safety, tolerability, pharmacokinetics and efficacy of KM257 by itself and combined with selected chemotherapy agents in patients with advanced HER2-positive or expressing…
- Trial name
- NCT05320874
- Testing
- KM257 Bispecific antibody
- Where
- China
- Volunteers
- 232 people
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Solid Tumor, Carcinoma
Propofol vs Sevo for Paediatric Tumor Surgery
Background: Retrospective studies and meta-analyses have shown a reduction in 5-year survival following inhalational based compared to propofol based total intravenous (TIVA) anaesthesia for cancer surgery.
- Conditions
- Solid Tumor, Carcinoma, Malignancy, Cancer
- Trial name
- NCT04475705
- Testing
- propofol, sevoflurane
- Where
- Hong Kong
- Volunteers
- 100 people
- Sponsor
- Hong Kong Children's Hospital
Solid Tumor
An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors
This study is a single-center exploratory clinical trial. It is estimated that 9-24 subjects will be enrolled. The "3+3" dose escalation design is adopted.
- Trial name
- NCT05166070
- Testing
- RD133
- Where
- China
- Volunteers
- 24 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University